September 17, 2010 at 08:30 AM EDT
Antares Pharma Announces Planned Departure of Senior Executive

Antares Pharma, Inc. (NYSE Amex: AIS) today announced that Dario Carrara, Ph.D. has resigned from his position as Senior Vice President and Managing Director – Pharmaceutical Group in Muttenz, Switzerland. Dr. Carrara’s resignation is to be effective on December 31, 2010. Dr. Carrara will transition to Ferring International Center SA, who purchased from Antares certain assets and assumed a leased facility in Switzerland along with a majority of the site’s employees at the time of the purchase in November 2009.

Paul K. Wotton, Ph.D., President and Chief Executive Officer, stated, “On behalf of the board of directors and everyone associated with Antares I would like to thank Dario for his many contributions to the Company, culminating in the recent successful completion of the Anturol Phase 3 study. Our pharmaceutical development team located in Ewing, NJ remains on track to file an NDA for Anturol in 2010. We wish Dario well in his new role at Ferring, an important partner of Antares.”

Dr. Carrara said, “I have enjoyed working with the team at Antares on development programs including Anturol, Libigel and Elestrin and look forward to continuing the work with the ATD technology platform at Ferring.”

About Antares Pharma

Antares Pharma focuses on self-injection delivery technologies and topical gel-based pharmaceutical products. The Company's subcutaneous and intramuscular injection technology platforms include VIBEXTM disposable pressure-assisted auto injectors, ValeoTM/VisionTM reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, Antares Pharma has a multi-product deal with Teva Pharmaceutical Industries, Ltd that includes Tev-Tropin® human growth hormone and a partnership with Ferring Pharmaceuticals. In the gel-based area, the Company's lead product candidate is Anturol® an oxybutynin ATDTM gel for the treatment of OAB (overactive bladder). Antares also has a partnership with BioSante that includes LibiGel® (transdermal testosterone gel) in Phase 3 clinical development for the treatment of female sexual dysfunction (FSD), and Elestrin® (estradiol gel) indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and currently marketed in the U.S. Antares Pharma has corporate headquarters in Ewing, New Jersey, with subsidiaries performing research, development and product commercialization activities in Minneapolis, Minnesota and Muttenz, Switzerland.

Contacts:

Antares Pharma, Inc.
Robert F. Apple
Chief Financial Officer
609-359-3020
or
Investors:
Westwicke Partners, LLC
John Woolford
443-213-0506
john.woolford@westwicke.com
or
Media:
Tiberend Strategic Advisors, Inc.
Tamara Bright
212-827-0020
tbright@tiberendstrategicadvisors.com
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here